<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00603044</url>
  </required_header>
  <id_info>
    <org_study_id>15868B</org_study_id>
    <secondary_id>15868B</secondary_id>
    <nct_id>NCT00603044</nct_id>
  </id_info>
  <brief_title>Mechanism of Action of Fluticasone Furoate in Childhood Obstructive Sleep Apnea Syndrome</brief_title>
  <official_title>Mechanism of Action of Fluticasone Furoate in Childhood Obstructive Sleep Apnea Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to find out how a nasal spray (fluticasone furoate),
      sometimes given to children with obstructive sleep apnea syndrome (OSAS), works on certain
      cells within a child's adenoids. We hypothesize that intranasal steroids lead to an
      upregulation of T regulatory cells in the adenoid tissues of children with OSAS. This will
      result in a local reduction in inflammation and edema explaining the improvement in OSAS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective was to determine the effect of intranasal corticosteroid therapy on
      T-regulatory cells and other inflammatory cytokines in adenoid tissues in children with
      obstructive sleep apnea syndrome.Children were randomized to either no treatment or treatment
      with fluticasone furoate nasal spray, 55 Î¼g/nostril daily, for 2 weeks before
      adenotonsillectomy. Adenoid tissue was obtained at the time of the procedure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of CD25 Pos/FoxP3 Positive Cells</measure>
    <time_frame>following adenoidectomy (2 weeks)</time_frame>
    <description>The number of tissue T-regulatory cells, as determined by staining with FOXP3, CD4, and CD25</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of CD4 Pos/FOXP3 Positive Cells</measure>
    <time_frame>following adenoidectomy (2 weeks)</time_frame>
    <description>The number of tissue T-regulatory cells, as determined by staining with FOXP3, CD4, and CD25</description>
  </primary_outcome>
  <primary_outcome>
    <measure>IL-10 Staining Intensity</measure>
    <time_frame>following adenoidectomy (2 weeks)</time_frame>
    <description>IL-10 staining intensity on immunohistochemical staining of adenoid tissues. Units are Integrated optical density (IOD)/100 micrometer squared.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of IL-10 Secreted by Adenoid Cells After PHA Stimulation</measure>
    <time_frame>following adenoidectomy (2 weeks)</time_frame>
    <description>Amount of IL-10 secreted by adenoid cells after PHA stimulation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Amount of TGF Secreted by Adenoid Cells After PHA Stimulation</measure>
    <time_frame>following adenoidectomy (2 weeks)</time_frame>
    <description>Amount of TGF secreted by adenoid cells after PHA stimulation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adjusted Volume of the Removed Adenoids</measure>
    <time_frame>following adenoidectomy (2 weeks)</time_frame>
    <description>To adjust for different weights of the children, the volume of the adenoids, estimated by water displacement in the operating room in mL, was divided by the respective weights (kg) of the patients and multiplied by 100.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Childhood Obstructive Sleep Apnea Syndrome (OSAS)</condition>
  <arm_group>
    <arm_group_label>Fluticasone furoate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>55 mcg/nostril once daily for 2 weeks prior to adenotonsillectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone furoate</intervention_name>
    <description>treatment with fluticasone furoate (55 mcg/nostril once daily) for 2 weeks prior to adenotonsillectomy</description>
    <arm_group_label>Fluticasone furoate</arm_group_label>
    <other_name>Veramyst</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: between 2 and 12 years

          -  Polysomnogram results showing AHI &gt;5/hr irrespective of saturations

          -  No other significant medical problems except well controlled asthma

          -  No chronic medication intake except bronchodilators and leukotriene receptor
             antagonists

          -  No systemic steroids within the past month

          -  No intranasal steroids within the past 2 weeks

        Exclusion Criteria:

          -  Patients with OSAS who are overweight (BMI&gt;95th percentile for age) or who have
             neurological or craniofacial abnormalities as these tend to have OSAS related to these
             factors per se.

          -  Females of the specified age group who have already had their first period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fuad M Baroody, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2008</study_first_submitted>
  <study_first_submitted_qc>January 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2008</study_first_posted>
  <results_first_submitted>April 13, 2015</results_first_submitted>
  <results_first_submitted_qc>April 29, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 4, 2015</results_first_posted>
  <last_update_submitted>April 29, 2015</last_update_submitted>
  <last_update_submitted_qc>April 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fluticasone Furoate</title>
          <description>55 mcg/nostril once daily for 2 weeks prior to adenotonsillectomy
fluticasone furoate: treatment with fluticasone furoate (55 mcg/nostril once daily) for 2 weeks prior to adenotonsillectomy</description>
        </group>
        <group group_id="P2">
          <title>No Treatment</title>
          <description>Subjects in this arm received no treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fluticasone Furoate</title>
          <description>55 mcg/nostril once daily for 2 weeks prior to adenotonsillectomy
fluticasone furoate: treatment with fluticasone furoate (55 mcg/nostril once daily) for 2 weeks prior to adenotonsillectomy</description>
        </group>
        <group group_id="B2">
          <title>No Treatment</title>
          <description>Subjects in this arm received no treatment.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.24" spread="3.12"/>
                    <measurement group_id="B2" value="5.93" spread="3.32"/>
                    <measurement group_id="B3" value="5.62" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of CD25 Pos/FoxP3 Positive Cells</title>
        <description>The number of tissue T-regulatory cells, as determined by staining with FOXP3, CD4, and CD25</description>
        <time_frame>following adenoidectomy (2 weeks)</time_frame>
        <population>Some subjects were excluded due to technical issues.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Furoate</title>
            <description>55 mcg/nostril once daily for 2 weeks prior to adenotonsillectomy
fluticasone furoate: treatment with fluticasone furoate (55 mcg/nostril once daily) for 2 weeks prior to adenotonsillectomy</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Subjects in this arm received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of CD25 Pos/FoxP3 Positive Cells</title>
          <description>The number of tissue T-regulatory cells, as determined by staining with FOXP3, CD4, and CD25</description>
          <population>Some subjects were excluded due to technical issues.</population>
          <units>cells per High power field (HPF)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" lower_limit="3.1" upper_limit="35.2"/>
                    <measurement group_id="O2" value="14.6" lower_limit="3.1" upper_limit="36.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of CD4 Pos/FOXP3 Positive Cells</title>
        <description>The number of tissue T-regulatory cells, as determined by staining with FOXP3, CD4, and CD25</description>
        <time_frame>following adenoidectomy (2 weeks)</time_frame>
        <population>Some subjects were excluded due to technical issues.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Furoate</title>
            <description>55 mcg/nostril once daily for 2 weeks prior to adenotonsillectomy
fluticasone furoate: treatment with fluticasone furoate (55 mcg/nostril once daily) for 2 weeks prior to adenotonsillectomy</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Subjects in this arm received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of CD4 Pos/FOXP3 Positive Cells</title>
          <description>The number of tissue T-regulatory cells, as determined by staining with FOXP3, CD4, and CD25</description>
          <population>Some subjects were excluded due to technical issues.</population>
          <units>cells per High power field (HPF)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" lower_limit="3.3" upper_limit="38.8"/>
                    <measurement group_id="O2" value="21.4" lower_limit="3.7" upper_limit="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>IL-10 Staining Intensity</title>
        <description>IL-10 staining intensity on immunohistochemical staining of adenoid tissues. Units are Integrated optical density (IOD)/100 micrometer squared.</description>
        <time_frame>following adenoidectomy (2 weeks)</time_frame>
        <population>Some subjects were excluded due to technical issues.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Furoate</title>
            <description>55 mcg/nostril once daily for 2 weeks prior to adenotonsillectomy
fluticasone furoate: treatment with fluticasone furoate (55 mcg/nostril once daily) for 2 weeks prior to adenotonsillectomy</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Subjects in this arm received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>IL-10 Staining Intensity</title>
          <description>IL-10 staining intensity on immunohistochemical staining of adenoid tissues. Units are Integrated optical density (IOD)/100 micrometer squared.</description>
          <population>Some subjects were excluded due to technical issues.</population>
          <units>IOD/100 micrometer squared</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="437.4" spread="85.6"/>
                    <measurement group_id="O2" value="479.8" spread="6.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Amount of IL-10 Secreted by Adenoid Cells After PHA Stimulation</title>
        <description>Amount of IL-10 secreted by adenoid cells after PHA stimulation</description>
        <time_frame>following adenoidectomy (2 weeks)</time_frame>
        <population>Some subjects were excluded due to technical issues.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Furoate</title>
            <description>55 mcg/nostril once daily for 2 weeks prior to adenotonsillectomy
fluticasone furoate: treatment with fluticasone furoate (55 mcg/nostril once daily) for 2 weeks prior to adenotonsillectomy</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Subjects in this arm received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of IL-10 Secreted by Adenoid Cells After PHA Stimulation</title>
          <description>Amount of IL-10 secreted by adenoid cells after PHA stimulation</description>
          <population>Some subjects were excluded due to technical issues.</population>
          <units>picogram per milliliter (pg/mL)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115" lower_limit="6" upper_limit="204"/>
                    <measurement group_id="O2" value="210" lower_limit="15" upper_limit="510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Amount of TGF Secreted by Adenoid Cells After PHA Stimulation</title>
        <description>Amount of TGF secreted by adenoid cells after PHA stimulation</description>
        <time_frame>following adenoidectomy (2 weeks)</time_frame>
        <population>Some subjects were excluded due to technical issues.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Furoate</title>
            <description>55 mcg/nostril once daily for 2 weeks prior to adenotonsillectomy
fluticasone furoate: treatment with fluticasone furoate (55 mcg/nostril once daily) for 2 weeks prior to adenotonsillectomy</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Subjects in this arm received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of TGF Secreted by Adenoid Cells After PHA Stimulation</title>
          <description>Amount of TGF secreted by adenoid cells after PHA stimulation</description>
          <population>Some subjects were excluded due to technical issues.</population>
          <units>picogram per milliliter (pg/mL)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="944" lower_limit="519" upper_limit="2555"/>
                    <measurement group_id="O2" value="906" lower_limit="598" upper_limit="1071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adjusted Volume of the Removed Adenoids</title>
        <description>To adjust for different weights of the children, the volume of the adenoids, estimated by water displacement in the operating room in mL, was divided by the respective weights (kg) of the patients and multiplied by 100.</description>
        <time_frame>following adenoidectomy (2 weeks)</time_frame>
        <population>Some subjects were excluded due to technical issues.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Furoate</title>
            <description>55 mcg/nostril once daily for 2 weeks prior to adenotonsillectomy
fluticasone furoate: treatment with fluticasone furoate (55 mcg/nostril once daily) for 2 weeks prior to adenotonsillectomy</description>
          </group>
          <group group_id="O2">
            <title>No Treatment</title>
            <description>Subjects in this arm received no treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Adjusted Volume of the Removed Adenoids</title>
          <description>To adjust for different weights of the children, the volume of the adenoids, estimated by water displacement in the operating room in mL, was divided by the respective weights (kg) of the patients and multiplied by 100.</description>
          <population>Some subjects were excluded due to technical issues.</population>
          <units>mL/kg x100</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.0" spread="2.7"/>
                    <measurement group_id="O2" value="16.8" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Fluticasone Furoate</title>
          <description>55 mcg/nostril once daily for 2 weeks prior to adenotonsillectomy
fluticasone furoate: treatment with fluticasone furoate (55 mcg/nostril once daily) for 2 weeks prior to adenotonsillectomy</description>
        </group>
        <group group_id="E2">
          <title>No Treatment</title>
          <description>Subjects in this arm received no treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Fuad Baroody, MD</name_or_title>
      <organization>The University of Chicago Medicine</organization>
      <phone>(773) 702-4790</phone>
      <email>fbaroody@surgery.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

